Medical devices to prevent or inhibit restenosis

Details Medical devices to prevent or inhibit restenosis Medical devices to prevent or inhibit restenosis

2007-01-25

2011-11-29

Azpuru, Carlos (Department: 1617)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S489000

Reexamination Certificate

active

08067024

ABSTRACT:
Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain anti-inflammatory agents, are disclosed. The anti-inflammatory agents are selected from the group consisting of Sanglifehrin A, Sanglifehrin B, Sanglifehrin C, Sanglifehrin D, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the anti-inflammatory agent with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-anti-inflammatory agent blends are disclosed. Additionally, medical devices having a coating comprising at least one anti-inflammatory agent in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

REFERENCES:
patent: 6547803 (2003-04-01), Seward et al.
patent: 6585764 (2003-07-01), Wright et al.
patent: 2002/0198512 (2002-12-01), Seward et al.
patent: 2003/0055400 (2003-03-01), Seward et al.
patent: 0623354 (2002-10-01), None
patent: WO97/02285 (1997-01-01), None
patent: WO98/07743 (1998-02-01), None
Fehr, T.: et al.: J. Antibiot. 1999, 52(5): 474.
Sanglier, J.-J. ; et al., J. Antibiot. 1999 52(5) : 466.
Allen, A. ; et al., J. Immunol. 2004, 172(8): 4797.
Woltman, A.M.; et al., J. Immunol. 2004, 172(10): 6482.
Steinschulte, C.; et al., Am. J. Transplant 2004, 4 (Suppl. 8): Abst. 129.
Nicolaou, K.C.; et al.; “Total Synthesis of the Novel Immunosuppressant Sanglifehrin A” J. Am. Chem. Soc. 2000, 122, pp. 3830-3838.
Zhao L., et al.; “Selective Interleukin-12 Synthesis Defect in 12/15-Lipoxygenase-Deficient Macrophages Associated with Reduced Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia” The Journal of Biological Chemistry, vol. 277, No. 38, Issue of Sep. 20, pp. 35350-35356, 2002.
Nicolaou, K.C., et al. : “Total Synthesis of Sanglifehrin A” Angew. Chem.Int.Ed. 1999, 38, No. 16, pp. 2447-2451.
Zhang, L., et al. “Inhibition of Cell Cycle Progression by the Novel Cyclophilin Ligand Sanglifehrin A is Mediated Through the NFkB-Dependent Activation of p53,” The Journal of Biological Chemistry, vol. 276, No. 47, Issue of Nov. 23, pp. 43534-43540, 2001.
Clarke, S., et al. “Sanglifehrin A Acts as a Potent Inhibitor of the Mitochondrial Permeability Transition and Reperfusion Injury of the Heart by Binding to Cyclophilin-D at a Different Site from Cyclosporin A,” The Journal of Biological Chemistry, vol. 277, No. 38, Issue of Sep. 20, pp. 34793-34799, 2002.

Affiliated with

Also associated with

Rating

Medical devices to prevent or inhibit restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical devices to prevent or inhibit restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical devices to prevent or inhibit restenosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4277919